Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Oral Drug Delivery Systems: Continuous-Release Systems

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...

Modified-Release Drug Delivery Systems: Overview

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...

Drug Delivery Systems: Different Types

Drug Delivery Systems: Different Types

Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...

Modified-Release Drug Delivery Systems: Rate-Programmed II

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...

Modified-Release Drug Delivery Systems: Drug Release Characteristics

Modified-Release Drug Delivery Systems: Drug Release Characteristics

Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...

Drug Delivery: Miscellaneous Routes

Drug Delivery: Miscellaneous Routes

Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Utilizing Decision Analysis to Assess the Safety of Providing Medication for Addiction Treatment to Professionals With Substance Use Disorder.

Journal of addiction medicine·2025

Same author

Synergistic Adhesion and Shape Deformation in Nanowire-Structured Liquid Crystal Elastomers.

Advanced materials (Deerfield Beach, Fla.)·2025

Same author

Functional nanoporous graphene superlattice.

Nature communications·2024

Same author

Single-molecule visualization determines conformational substate ensembles in β-sheet-rich peptide fibrils.

Science advances·2023

Same author

Staggered circular nanoporous graphene converts electromagnetic waves into electricity.

Nature communications·2023

Same author

Design of a self-cleanable multilevel anticounterfeiting interface through covalent chemical modulation.

Materials horizons·2023

Search research articles

Related Experiment Video

Updated: Jul 19, 2026

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

Abuse-resistant drug delivery.

Robert L DuPont¹, Peter B Bensinger

¹Georgetown University School of Medicine, Washington, DC, USA.

Pediatric Annals

|September 22, 2006

Summary

Educating physicians and patients on the risks of prescription stimulant misuse is crucial. Developing abuse-resistant drug delivery systems offers a promising new strategy to reduce nonmedical use of ADHD medications.

Area of Science:

Pharmacology
Public Health
Addiction Medicine

Background:

Nonmedical use of prescription stimulants, including those for Attention Deficit Hyperactivity Disorder (ADHD), poses significant public health risks.
Concerns about widespread misuse threaten appropriate patient access to beneficial ADHD medications.

Purpose of the Study:

To explore strategies for reducing the nonmedical use of prescription controlled substances.
To highlight the potential of abuse-deterrent drug delivery systems as a novel prevention paradigm.

Main Methods:

Review of current strategies for controlling prescription drug abuse.
Analysis of the potential benefits of abuse-resistant formulations and delivery systems.
Discussion of the need for standards and incentives for developing abuse-deterrent medications.

More Related Videos

Disposable Dosators Intended for Dry Powder Delivery to Mice

Disposable Dosators Intended for Dry Powder Delivery to Mice

Published on: August 18, 2023

Novel Apparatus and Method for Drug Reinforcement

Novel Apparatus and Method for Drug Reinforcement

Published on: August 20, 2010

Related Experiment Videos

Last Updated: Jul 19, 2026

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

Disposable Dosators Intended for Dry Powder Delivery to Mice

Disposable Dosators Intended for Dry Powder Delivery to Mice

Published on: August 18, 2023

Novel Apparatus and Method for Drug Reinforcement

Novel Apparatus and Method for Drug Reinforcement

Published on: August 20, 2010

Main Results:

Physician education on risks and patient-specific abuse potential is a key intervention.
Abuse-resistant drug delivery systems present a promising new approach to curb nonmedical use.
Development of standardized assessments for abuse resistance is necessary.

Conclusions:

A multi-faceted approach involving education and innovative drug delivery systems is essential to combat prescription stimulant abuse.
Further development and implementation of abuse-deterrent formulations are critical for reducing nonmedical use of ADHD medications.
Establishing clear standards and incentives will accelerate the adoption of abuse-resistant technologies.